News
ADVM
14.47
-1.30%
-0.19
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
TipRanks · 19h ago
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
NASDAQ · 1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
Weekly Report: what happened at ADVM last week (0318-0322)?
Weekly Report · 3d ago
Adverum Biotechnologies files for $200M mixed securities shelf
Adverum Biotechnologies files for $200M mixed securities shelf. The company filed a prospectus related to the offer and sell up to an aggregate amount of $200,000,000. Adverum's stock is down 2.7% in pre-market trading.
Seeking Alpha · 6d ago
Positive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial Position
TipRanks · 03/21 06:46
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. Dipped 31.7% to $4.91 on Wednesday. ETAO International Co., Ltd. Shares shot up 111.5% after the company announced a reverse stock split. NuScale Power Corporation shares tumbled around 35% after spiking 17% on Tuesday.
Benzinga · 03/20 18:03
Brexit Uncertainty: Navigating New Risks and Regulatory Hurdles for Adverum Biotechnologies
TipRanks · 03/20 06:00
Ocular Therapeutics' Impressive Surge: A Strategic Insight
Ocular Therapeutics' stock has surged 184% in six months, driven by promising clinical assets in eye disease treatments. The company is developing clinical assets for chronic ailments of the eye. Ocular's Paxtrava faces tough competition and logistical challenges in glaucoma treatment. Investment recommendation: Hold OCUL stock.
Seeking Alpha · 03/19 20:04
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.02% to 1689.96. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is +0.01% to 1378.25.
Seeking Alpha · 03/19 14:00
Adverum Biotechnologies Price Target Maintained With a $4.00/Share by Chardan Capital
Dow Jones · 03/19 13:03
Chardan Capital Reiterates Buy on Adverum Biotechnologies, Maintains $4 Price Target
Benzinga · 03/19 12:54
Adverum Biotechnologies Price Target Cut to $2.00/Share From $3.00 by RBC Capital
Dow Jones · 03/19 12:23
Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital
Dow Jones · 03/19 12:23
RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $2
Benzinga · 03/19 12:13
Adverum Biotechnologies (ADVM) Initiated with a Hold at RBC Capital
RBC Capital analyst Luca Issi initiated coverage with a Hold rating on Adverum Biotechnologies. The company has a one-year high of $2.97 and a low of $0.68. Issi is an analyst with an average return of -20.5% and a 23.66%.
TipRanks · 03/19 10:45
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. American Tower, Lennar and Nike among companies with revised targets on Tuesday. Analysts cut target prices for American Tower and Lennar, raise targets for others. Zoom Video Communications, Darden Restaurants and others also see analyst downgrades.
Reuters · 03/19 07:17
ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023
Adverum Biotechnologies reported earnings per share of -23 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -34 cents. Adverum reported results for the last quarter of 2013.
Investorplace · 03/19 02:53
Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen
TipRanks · 03/18 21:55
Adverum Biotechnologies GAAP EPS of -$0.23 beats by $0.11
Adverum Biotechnologies GAAP EPS of -$0.23 beats by $0.11. Cash, cash equivalents and short-term investments were $96.5 million as of December 31, 2023. Adverum expects its cash to fund operations into late 2025. Shares -5.1%.
Seeking Alpha · 03/18 20:35
More
Webull provides a variety of real-time ADVM stock news. You can receive the latest news about Adverum Biotech through multiple platforms. This information may help you make smarter investment decisions.
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.